Bharti Airtel share price falls as Reliance Jio launches cheaper plans; HSBC says ‘no threat’, rates ‘Buy’ Reliance Jio’s newly launched postpaid family plans have made Bharti Airtel investors nervous that the move could disrupt the telecom industry. The shares of Bharti Airtel fell 1.24% to Rs 747 in the intraday trade on Thursday. Following the trend, Vodafone Idea shares hit a new 52-week low, falling 2.5% to Rs 6.25. HSBC Global Research said that there will be little disruption from the new plans in the industry and reiterated the BUY rating for Bharti Airtel stock. “Bharti Airtel family plans are priced at a premium of 0.3% to 34.7% to Jio, on varying scenarios of the number of add-on connections and price adjustments for bundled content/ OTT (Exhibits 5-6). We estimate subscribers with family plans contributed around 2.6-5.1% of Bharti Airtel’s India mobile revenue (Exhibit 4). In a worst-case scenario, if Bharti Airtel needed to cut pricing by c15% to defend these subscribers, we estimate India’s mobile revenue could fall by 0.4-0.8% and consolidated EBITDA could decline by 0.2-0.4%,” HSBC said. “We think Bharti Airtel is well positioned for ROIC improvement, with margin expansion and improving invested capital turnover. We expect robust mobile revenue growth and ARPU to rise, driven by: (1) sub-migration from 2G to 4G; (2) sub-migration to higher bucket data plans due to a surge in data usage; (3) gains in high-value postpaid subs; and (4) segmented tariff hikes. We expect consolidated revenue and EBITDA CAGRs of c12% and c13%, respectively, over FY22-25e. Our target price is unchanged at Rs 970, and we reiterate our Buy rating on the stock,” analysts at HSBC said.
Also Read: Zerodha’s Nikhil Kamath tells when to buy stocks, shares Buffett formula to find the right time
FII and DII trades: Foreign Institutional Investors (FII) have been net buyers of domestic stocks for successive days now. On Wednesday, FIIs pumped in Rs 2,347 crore. Domestic Institutional Investors (DII) have been net sellers, pulling out Rs 510 crore yesterday.
IPO watch: Syrma SGS Technology enters the final day of bidding today. So far the issue, that opened last week, has been subscribed 2.27 times. Retail investors have subscribed their portion 2.66 times while NIIs have bid for their quota 3.58 times and QIB portion has been bid for 0.71 times.
BDENZA ORAL SOLUTION represents a significant advancement in prostate cancer therapy, offering relief and hope to millions of patients worldwide.
“BDENZA represents a paradigm shift in prostate cancer therapy. Its introduction aligns with our relentless pursuit to provide accessible and patient-centric healthcare solutions. This first-of-its-kind oral solution that addresses the challenges faced by many patients, offering convenience, reduced side effects, and a palatable sugar-free taste and affordability,” Raheel Shah, BDR Group Director (Business Development) said in a statement.